| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2143241 | Lung Cancer | 2008 | 7 Pages |
Abstract
This was the largest multicenter prospective clinical study of NSCLC in Taiwan. The results demonstrated the excellent response rates, time-to-progression and overall survival of erlotinib in a large population of Taiwanese NSCLC patients who had been previously treated with chemotherapy or radiotherapy.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Reury-Perng Perng, Chih-Hsin Yang, Yuh-Min Chen, Gee-Chen Chang, Meng-Chih Lin, Ruey-Kuen Hsieh, Nei-Min Chu, Ruay-Sheng Lai, Wu-Chou Su, Chao-Jung Tsao, Te-Chun Hsia, Hao-Cheng Chen, Chih-Hung Chen, Ming-Shyan Huang, Jui-Long Wang, Ming-Lin Ho,